Blinding
BLIND
Only the study statistician and data manager will have access to the allocation to treatment order prior to randomization. Outcomes assessors will be blind to treatment condition throughout the study. They will conduct end-of-treatment (12 week) and 6-, 9-, and 12-month assessments, and bi-annual calls monitoring for MACE/mortality. If the assessor learns a participant’s randomization assignment through any means (i.e., becomes unblinded), another assessor will take over that participant’s remaining assessments/calls. The study cardiologists will be blind to treatment condition throughout the study and will code records for the occurrence and type of MACE.